Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

CATX

(1.2)
Stock Price

2,85 USD

-64.65% ROA

-26.18% ROE

-172.16x PER

Market Cap.

888.022.809,00 USD

3.35% DER

0% Yield

-18927.3% NPM

Perspective Therapeutics, Inc. Stock Analysis

Perspective Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Perspective Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.67x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

Negative ROE (-20.75%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-41.11%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Perspective Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Perspective Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Perspective Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Perspective Therapeutics, Inc. Revenue
Year Revenue Growth
1993 6.788.104
1994 7.816.949 13.16%
1995 8.258.189 5.34%
1996 7.848.460 -5.22%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 1.994.306 100%
2006 5.738.033 65.24%
2007 7.158.690 19.85%
2008 5.417.815 -32.13%
2009 5.286.084 -2.49%
2010 5.238.973 -0.9%
2011 5.071.088 -3.31%
2012 4.525.233 -12.06%
2013 4.219.158 -7.25%
2014 4.606.539 8.41%
2015 4.769.276 3.41%
2016 4.761.000 -0.17%
2017 5.923.000 19.62%
2018 7.314.000 19.02%
2019 9.680.000 24.44%
2020 10.053.000 3.71%
2021 10.795.000 6.87%
2022 6.000.000 -79.92%
2022 7.104.000 15.54%
2023 7.636.000 6.97%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Perspective Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 450.425 100%
2006 1.345.163 66.52%
2007 1.358.075 0.95%
2008 958.665 -41.66%
2009 340.959 -181.17%
2010 465.333 26.73%
2011 730.579 36.31%
2012 627.107 -16.5%
2013 668.803 6.23%
2014 614.771 -8.79%
2015 528.049 -16.42%
2016 965.000 45.28%
2017 1.746.000 44.73%
2018 1.474.000 -18.45%
2019 1.126.000 -30.91%
2020 1.427.000 21.09%
2021 2.582.000 44.73%
2022 22.612.000 88.58%
2022 2.602.000 -769.02%
2023 22.884.000 88.63%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Perspective Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 7.584 100%
2001 19.022 60.13%
2002 9.095 -109.15%
2003 30.000 69.68%
2005 4.924.022 99.39%
2006 8.300.070 40.67%
2007 7.293.212 -13.81%
2008 2.792.611 -161.16%
2009 2.440.140 -14.44%
2010 2.422.884 -0.71%
2011 2.355.015 -2.88%
2012 2.294.173 -2.65%
2013 2.488.219 7.8%
2014 2.400.353 -3.66%
2015 3.786.657 36.61%
2016 3.918.000 3.35%
2017 4.165.000 5.93%
2018 4.172.000 0.17%
2019 4.571.000 8.73%
2020 4.691.000 2.56%
2021 6.621.000 29.15%
2022 20.292.000 67.37%
2022 10.866.000 -86.75%
2023 18.784.000 42.15%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Perspective Therapeutics, Inc. EBITDA
Year EBITDA Growth
1993 -1.779.930
1994 -436.432 -307.84%
1995 -2.688.701 83.77%
1996 13.865 19492%
1997 -234.323 105.92%
1998 -15.530 -1408.84%
1999 -14.149 -9.76%
2000 -15.569 9.12%
2001 -7.584 -105.29%
2002 -19.022 60.13%
2003 -9.095 -109.15%
2005 -6.154.426 99.85%
2006 -8.984.583 31.5%
2007 -7.467.847 -20.31%
2008 -5.537.646 -34.86%
2009 -3.012.020 -83.85%
2010 -2.071.039 -45.44%
2011 -2.920.855 29.09%
2012 -3.327.442 12.22%
2013 -3.890.709 14.48%
2014 -4.053.442 4.01%
2015 -4.393.007 7.73%
2016 -6.189.000 29.02%
2017 -6.700.000 7.63%
2018 -5.302.000 -26.37%
2019 -3.476.000 -52.53%
2020 -3.428.000 -1.4%
2021 -7.391.000 53.62%
2022 -44.312.000 83.32%
2022 -14.838.000 -198.64%
2023 -39.228.000 62.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Perspective Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
1993 367.894
1994 822.275 55.26%
1995 795.607 -3.35%
1996 1.164.639 31.69%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 -1.820.816 100%
2006 -54.597 -3235.01%
2007 -151.434 63.95%
2008 -353.332 57.14%
2009 725.797 148.68%
2010 1.157.417 37.29%
2011 703.204 -64.59%
2012 150.176 -368.25%
2013 -196.471 176.44%
2014 167.393 217.37%
2015 129.154 -29.61%
2016 838.000 84.59%
2017 1.842.000 54.51%
2018 3.047.000 39.55%
2019 5.124.000 40.53%
2020 5.121.000 -0.06%
2021 4.616.000 -10.94%
2022 -1.360.000 439.41%
2022 1.634.000 183.23%
2023 1.848.000 11.58%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Perspective Therapeutics, Inc. Net Profit
Year Net Profit Growth
1993 -437.594
1994 -939.169 53.41%
1995 -2.151.984 56.36%
1996 -426.078 -405.07%
1997 -139.549 -205.33%
1998 1.824.546 107.65%
1999 -65.649 2879.24%
2000 235.110 127.92%
2001 -59.084 497.92%
2002 -60.027 1.57%
2003 75.757 179.24%
2005 -8.218.130 100.92%
2006 -9.605.155 14.44%
2007 -8.557.507 -12.24%
2008 -6.160.841 -38.9%
2009 -4.033.856 -52.73%
2010 -2.842.213 -41.93%
2011 -3.488.905 18.54%
2012 -3.856.596 9.53%
2013 -5.959.122 35.28%
2014 -3.681.051 -61.89%
2015 -4.710.808 21.86%
2016 -6.162.000 23.55%
2017 -6.700.000 8.03%
2018 -4.850.000 -38.14%
2019 -3.269.000 -48.36%
2020 -3.188.000 -2.54%
2021 -7.153.000 55.43%
2022 -44.424.000 83.9%
2022 -14.670.000 -202.82%
2023 -41.424.000 64.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Perspective Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 -2
1994 -3 66.67%
1995 -7 50%
1996 -1 -500%
1997 0 0%
1998 5 100%
1999 0 0%
2000 1 0%
2001 0 0%
2002 0 0%
2003 0 0%
2005 -1 0%
2006 -1 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Perspective Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
1993 -538.048
1994 -546.508 1.55%
1995 -1.124.379 51.39%
1996 -36.737 -2960.62%
1997 116.394 131.56%
1998 316.531 63.23%
1999 -7.415 4368.79%
2000 -14.733 49.67%
2001 -8.865 -66.19%
2002 -19.022 53.4%
2003 -1.009.857 98.12%
2005 -7.840.486 87.12%
2006 -9.677.434 18.98%
2007 -11.109.535 12.89%
2008 -4.044.487 -174.68%
2009 -2.719.866 -48.7%
2010 -2.576.124 -5.58%
2011 -2.543.072 -1.3%
2012 -3.068.961 17.14%
2013 -3.265.008 6%
2014 -3.673.105 11.11%
2015 -4.375.754 16.06%
2016 -6.261.000 30.11%
2017 -6.049.000 -3.5%
2018 -5.493.000 -10.12%
2019 -3.914.000 -40.34%
2020 -3.218.000 -21.63%
2021 -7.976.000 59.65%
2022 -8.627.000 7.55%
2022 -12.474.000 30.84%
2023 -10.337.000 -20.67%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Perspective Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1993 -518.187
1994 -501.830 -3.26%
1995 -1.083.134 53.67%
1996 -11.714 -9146.49%
1997 275.974 104.24%
1998 365.340 24.46%
1999 -7.415 5027.04%
2000 -14.733 49.67%
2001 -8.865 -66.19%
2002 -19.022 53.4%
2003 -9.857 -92.98%
2005 -7.003.077 99.86%
2006 -7.201.710 2.76%
2007 -7.725.298 6.78%
2008 -3.948.936 -95.63%
2009 -2.686.403 -47%
2010 -2.418.910 -11.06%
2011 -2.447.775 1.18%
2012 -3.056.267 19.91%
2013 -3.228.221 5.33%
2014 -3.521.858 8.34%
2015 -3.884.000 9.32%
2016 -5.712.000 32%
2017 -5.712.000 0%
2018 -5.049.000 -13.13%
2019 -3.641.000 -38.67%
2020 -2.837.000 -28.34%
2021 -7.710.000 63.2%
2022 -8.072.000 4.48%
2022 -12.172.000 33.68%
2023 -10.110.000 -20.4%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Perspective Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1993 19.861
1994 44.678 55.55%
1995 41.245 -8.32%
1996 25.023 -64.83%
1997 159.580 84.32%
1998 48.809 -226.95%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 1.000.000 100%
2005 837.409 -19.42%
2006 2.475.724 66.18%
2007 3.384.237 26.85%
2008 95.551 -3441.81%
2009 33.463 -185.54%
2010 157.214 78.71%
2011 95.297 -64.97%
2012 12.694 -650.72%
2013 36.787 65.49%
2014 151.247 75.68%
2015 491.754 69.24%
2016 549.000 10.43%
2017 337.000 -62.91%
2018 444.000 24.1%
2019 273.000 -62.64%
2020 381.000 28.35%
2021 266.000 -43.23%
2022 555.000 52.07%
2022 302.000 -83.77%
2023 227.000 -33.04%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Perspective Therapeutics, Inc. Equity
Year Equity Growth
1993 295.714
1994 -643.455 145.96%
1995 -1.902.715 66.18%
1996 -2.071.627 8.15%
1997 -2.135.511 2.99%
1998 -1.224.096 -74.46%
1999 -1.282.326 4.54%
2000 -1.032.516 -24.19%
2001 -1.083.015 4.66%
2002 -564.202 -91.96%
2004 11.232.000 105.02%
2005 2.885.710 -289.23%
2006 22.716.225 87.3%
2007 15.774.930 -44%
2008 9.963.050 -58.33%
2009 6.195.881 -60.8%
2010 6.452.516 3.98%
2011 5.818.192 -10.9%
2012 5.366.246 -8.42%
2013 23.955.768 77.6%
2014 20.782.241 -15.27%
2015 16.401.053 -26.71%
2016 10.602.000 -54.7%
2017 5.030.000 -110.78%
2018 7.680.000 34.51%
2019 5.723.000 -34.2%
2020 67.406.000 91.51%
2021 61.277.000 -10%
2022 54.642.000 -12.14%
2022 108.653.000 49.71%
2023 98.770.000 -10.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Perspective Therapeutics, Inc. Assets
Year Assets Growth
1993 2.876.727
1994 1.963.738 -46.49%
1995 1.740.952 -12.8%
1996 1.311.966 -32.7%
1997 1.174.146 -11.74%
1998 955 -122847.23%
1999 959 0.42%
2000 926 -3.56%
2001 926 0%
2002 926 0%
2004 32.587.000 100%
2005 5.655.939 -476.16%
2006 26.076.162 78.31%
2007 17.811.893 -46.4%
2008 11.741.566 -51.7%
2009 7.942.795 -47.83%
2010 7.888.895 -0.68%
2011 7.505.482 -5.11%
2012 7.055.356 -6.38%
2013 26.549.255 73.43%
2014 23.003.284 -15.42%
2015 18.101.850 -27.08%
2016 12.269.000 -47.54%
2017 7.455.000 -64.57%
2018 9.422.000 20.88%
2019 8.699.000 -8.31%
2020 70.416.000 87.65%
2021 64.439.000 -9.28%
2022 58.091.000 -10.93%
2022 120.145.000 51.65%
2023 110.518.000 -8.71%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Perspective Therapeutics, Inc. Liabilities
Year Liabilities Growth
1993 2.581.013
1994 2.607.193 1%
1995 3.643.667 28.45%
1996 3.383.593 -7.69%
1997 3.309.657 -2.23%
1998 1.225.051 -170.16%
1999 1.283.285 4.54%
2000 1.033.442 -24.18%
2001 1.083.941 4.66%
2002 565.128 -91.8%
2004 21.355.000 97.35%
2005 2.770.229 -670.87%
2006 3.359.937 17.55%
2007 2.036.963 -64.95%
2008 1.778.516 -14.53%
2009 1.746.914 -1.81%
2010 1.436.379 -21.62%
2011 1.687.290 14.87%
2012 1.689.110 0.11%
2013 2.593.487 34.87%
2014 2.221.043 -16.77%
2015 1.700.797 -30.59%
2016 1.667.000 -2.03%
2017 2.425.000 31.26%
2018 1.742.000 -39.21%
2019 2.976.000 41.47%
2020 3.010.000 1.13%
2021 3.162.000 4.81%
2022 3.449.000 8.32%
2022 11.492.000 69.99%
2023 11.748.000 2.18%

Perspective Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.08
Price to Earning Ratio
-172.16x
Price To Sales Ratio
260.49x
POCF Ratio
-203.22
PFCF Ratio
-46.83
Price to Book Ratio
37.41
EV to Sales
256.19
EV Over EBITDA
-41.82
EV to Operating CashFlow
-48.03
EV to FreeCashFlow
-46.05
Earnings Yield
-0.01
FreeCashFlow Yield
-0.02
Market Cap
0,89 Bil.
Enterprise Value
0,87 Bil.
Graham Number
0.78
Graham NetNet
0.03

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
0.85
ROE
-0.21
Return On Assets
-0.16
Return On Capital Employed
-0.15
Net Income per EBT
1.35
EBT Per Ebit
0.88
Ebit per Revenue
-159.37
Effective Tax Rate
-0.17

Margins

Sales, General, & Administrative to Revenue
2.87
Research & Developement to Revenue
3.34
Stock Based Compensation to Revenue
0.48
Gross Profit Margin
1
Operating Profit Margin
-159.37
Pretax Profit Margin
-139.74
Net Profit Margin
-189.27

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.06
Free CashFlow per Share
-0.07
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.23
Capex to Depreciation
1.55
Return on Invested Capital
-0.22
Return on Tangible Assets
-0.65
Days Sales Outstanding
185.34
Days Payables Outstanding
429.41
Days of Inventory on Hand
112.49
Receivables Turnover
1.97
Payables Turnover
0.85
Inventory Turnover
3.24
Capex per Share
0

Balance Sheet

Cash per Share
0,06
Book Value per Share
0,35
Tangible Book Value per Share
0.08
Shareholders Equity per Share
0.35
Interest Debt per Share
0.01
Debt to Equity
0.03
Debt to Assets
0.03
Net Debt to EBITDA
0.7
Current Ratio
2.67
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
99433000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.7
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1053500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Perspective Therapeutics, Inc. Dividends
Year Dividends Growth

Perspective Therapeutics, Inc. Profile

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

CEO
Mr. Johan M. Spoor
Employee
116
Address
350 Hills Street
Richland, 99354

Perspective Therapeutics, Inc. Executives & BODs

Perspective Therapeutics, Inc. Executives & BODs
# Name Age
1 Dr. Markus Puhlmann M.B.A., M.D.
Chief Medical Officer
70
2 Dr. Michael K. Schultz Ph.D.
Chief Science Officer
70
3 Ms. Annie J. Cheng
Vice President of Investor Relations
70
4 Dr. Frances L. Johnson M.D.
Chief Innovation Officer
70
5 Mr. Amos Hedt BA, PGradDip
Chief Business Strategy Officer
70
6 Mr. David Hauser Ph.D.
Senior Vice President of Clinical Operations
70
7 Mr. Jonathan R. Hunt
Chief Financial Officer and Principal Financial & Accounting Officer
70
8 Mr. Andrew Bright
Executive Vice President of Brachytherapy
70
9 Mr. Johan M. Spoor
Chief Executive Officer & Director
70
10 Mr. Shane Cobb
Executive Vice President of Operations
70

Perspective Therapeutics, Inc. Competitors

NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
CVRx, Inc. Logo
CVRx, Inc.

CVRX

(1.0)
PAVmed Inc. Logo
PAVmed Inc.

PAVM

(1.8)
ProSomnus, Inc. Logo
ProSomnus, Inc.

OSA

(2.2)
Hyperfine, Inc. Logo
Hyperfine, Inc.

HYPR

(1.8)
Electromed, Inc. Logo
Electromed, Inc.

ELMD

(2.0)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
SI-BONE, Inc. Logo
SI-BONE, Inc.

SIBN

(1.0)